


STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade

Hannah Yang, Won Suk Lee, So Jung Kong, Chang Gon Kim, Joo Hoon Kim, Sei Kyung Chang, Sewha Kim, Gwangil Kim, Hong Jae Chon, Chan Kim

J Clin Invest. 2019. <https://doi.org/10.1172/JCI125413>.

Research In-Press Preview Angiogenesis Immunology

Graphical abstract



Find the latest version:

<https://jci.me/125413/pdf>



Original Article

STING Activation Reprograms Tumor Vasculatures and Synergizes with VEGFR2 Blockade

Hannah Yang^{1,4}, Won Suk Lee^{1,4}, So Jung Kong^{1,4}, Chang Gon Kim⁵, Joo Hoon Kim^{1,4},
Sei Kyung Chang², Sewha Kim³, Gwangil Kim³, Hong Jae Chon^{1,4*} and Chan Kim^{1,4*}

¹Medical Oncology, ²Department of Radiation Oncology, ³Department of Pathology, CHA Bundang Medical Center, CHA University, Seongnam 13495, Republic of Korea

⁴Laboratory of Translational Immuno-Oncology, CHA University, Seongnam 13488, Republic of Korea

⁵Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea

These authors contributed equally: Chan Kim, Hong Jae Chon

*Correspondence and requests for materials should be addressed to

Chan Kim, M.D., Ph.D. (Lead contact)

Medical Oncology,

CHA Bundang Medical Center, CHA University Medical School,

59 Yatap-ro, Bundang-gu, Seongnam, 13496, Korea

Phone: 82-31-881-7588

Fax: 82-31-780-3929

E-mail: chan@cha.ac.kr

Hong Jae Chon, M.D., Ph.D.

Medical Oncology,

CHA Bundang Medical Center, CHA University Medical School,

59 Yatap-ro, Bundang-gu, Seongnam, 13496, Korea

Phone: 82-31-780-3737

Fax: 82-31-780-3929

E-mail: minidoctor@cha.ac.kr

Conflict of Interest: The authors have declared that no conflict of interest exists.

Abstract

The stimulator of interferon genes (STING) signaling pathway is a critical link between innate and adaptive immunity, and induces anti-tumor immune responses. STING is expressed in vasculatures, but its role in tumor angiogenesis has not been elucidated. Here we investigated STING-induced tumor vascular remodeling and the potential of STING-based combination immunotherapy. Endothelial STING expression was correlated with enhanced T-cell infiltration and prolonged survival in human colon and breast cancer. Intratumoral STING activation with STING agonists (cGAMP or RR-CDA) normalized tumor vasculatures in implanted and spontaneous cancers, but not in STING-deficient mice. These were mediated by upregulation of type I/II interferon genes and vascular stabilizing genes (e.g., *Angpt1*, *Pdgfrb*, and *Col4a*). STING in non-hematopoietic cells is as important as STING in hematopoietic cells to induce a maximal therapeutic efficacy of exogenous STING agonist. Vascular normalizing effects of STING agonists were dependent on type I interferon signaling and CD8⁺ T cells. Notably, STING-based immunotherapy was maximally effective when combined with VEGFR2 blockade and/or immune checkpoint blockade (α PD-1 or α CTLA-4), leading to complete regression of immunotherapy-resistant tumors. Our data show that intratumoral STING activation can normalize tumor vasculature and the tumor microenvironment, providing a rationale for combining STING-based immunotherapy and anti-angiogenic therapy.

Introduction

The stimulator of interferon genes (STING) signaling pathway is the critical innate immune sensor for tumor detection (1–4). Upon activation in antigen-presenting cells within a tumor microenvironment (TME), the STING pathway drives robust production of type I interferons (IFNs) and enhances CD8⁺ T-cell cross-priming by tumor antigens, ultimately inducing adaptive anti-cancer immune responses (4–6). Based on these actions, various STING agonists have been developed for cancer therapy, which show promising anti-tumor activities as a monotherapy or combined with other therapeutics (6–11). However, while the STING pathway's role in dendritic cells is largely delineated, its contribution in other cellular components of the TME is not yet well-elucidated (4, 5, 12).

The inner lining of tumor vasculature comprises tumor endothelial cells that serve as a biologic interface between tumor and systemic immunity (13–15). The dynamic interplay between endothelium and immune cells is important for immune cell trafficking across the endothelial barrier, and determines the quality and amplitude of anti-cancer immune responses (16–19). Unfortunately, most tumor blood vessels are structurally malformed and functionally anergic, thus limiting T-lymphocyte survival and effector functions and suppressing anti-tumor immune responses in the TME (15, 16, 20). Alleviating these vascular abnormalities—a process known as vascular normalization—may relieve the intratumoral immunosuppression and eventually enhance cancer immunotherapy efficacy (14, 15, 21, 22).

Multiple lines of evidence suggest that STING signaling may be important in vascular biology. First, the STING protein is expressed in endothelial cells of both normal and tumor tissue (6, 12, 23). Particularly strong STING expression is observed in high-endothelial venule, which is a specialized endothelium for lymphocyte migration in lymphoid organs, suggesting the potential involvement of STING signaling in endothelial–lymphocyte interaction (24). Second, in various murine and human tumors, STING activation prompts endothelial cells to

produce type I IFNs, especially IFN- β (6, 23). Notably, endothelial cell-derived type I IFNs initiate anti-tumor responses even before dendritic cells and CD8⁺ T cells infiltrate the TME, and determine the overall magnitude of local and systemic immunity (23). Third, excessive STING activation is associated with aberrant vascular activation. Patients with a rare genetic syndrome, now termed SAVI (‘STING-associated vasculopathy with onset in infancy’), commonly exhibit mutations in the STING-encoding gene *TMEM173*, which lead to constitutive activation of IFN- β and IFN-response genes, resulting in fatal vasculitis (25, 26).

The presently available data suggest that endothelial cells may be another important target of STING agonists, and that STING-induced activation of endothelial cells could promote phenotypic and functional changes of tumor blood vessels. In the present study, we demonstrated the normalization of tumor vasculature upon STING activation and the therapeutic relevance of STING-targeted therapy in various tumor models, particularly when combined with an anti-angiogenic agent.

Results

Endothelial STING expression correlates with intratumoral CD8⁺ T-cell infiltration and favorable prognosis in human cancers.

To explore the clinical relevance of endothelial STING expression in human malignancies, we assessed the STING expression pattern in tumor tissues from 173 breast and 160 colorectal cancer patients. We detected distinct STING expression in tumor endothelial cells and immune cells (Figure 1, A and B; Supplementary Table 1). Intriguingly, CD8⁺ T-cell infiltration was increased near STING-expressing tumor vessels and was significantly correlated with endothelial STING expression levels (Figure 1, C and D). Moreover, compared with those with low STING expression, patients with high endothelial STING expression had better overall survival after cancer diagnosis (Figure 1, E and F; Supplementary Figure 1, A and B). High endothelial STING expression was also correlated with decreased prevalence of lymphovascular invasion within tumor tissues (Supplementary Table 2). This prognostic significance remained true even in multivariate Cox regression analysis using various clinical and molecular characteristics (Supplementary Table 3).

To gain deeper understanding of the role of endothelial STING in tumor growth, we utilized several mouse models. STING was expressed in CD31⁺ tumor endothelial as well as in hematopoietic cells such as dendritic cells and macrophages (Supplementary Figure 2A); however the level of STING expression in endothelial cells varied among different tumor models, with the CT26 colon cancer and LLC lung cancer models showing stronger endothelial STING expression compared with *MMTV-PyMT* breast cancer model (Supplementary Figure 2, B and C). Intriguingly, consistent with the findings from human cancers, the level of endothelial STING expression was also significantly correlated with intratumoral CD8⁺ T cells in mouse tumor models ($P = 0.001$, $R = 0.601$) (Supplementary Figure 2D). Moreover, when these tumors were treated with STING agonists, CT26, the tumor with modest STING

expression and most abundant intratumoral CD8⁺ T cells, showed the best response to treatment with STING agonists, while *MMTV-PyMT*, the tumor with the weakest STING expression, did not respond as well to treatment with a STING agonist alone (Supplementary Figure 2E). Therefore, the levels of baseline STING expression and intratumoral CD8⁺ T cells may be predictors of therapeutic response to STING agonist monotherapy.

Collectively, these findings suggest that endothelial STING signaling is associated with the prognosis of cancer patients and may play an important role during CD8⁺ T-cell-mediated anti-cancer immunity.

STING agonists promote CD8⁺ T-cell responses and tumor vascular normalization.

We next examined the temporal changes of tumor vasculatures and CD8⁺ T cells after intratumoral injection of STING agonist into LLC tumors (Figure 2, A and B). A single injection of RR-CDA (also called MIW815 or ADU-S100) led to dramatic changes in TME compared with PBS-injected control tumors. Whereas consistent angiogenesis was observed in control tumors, RR-CDA-treated tumors showed an abrupt decrease in CD31⁺ tumor vessels at one day after RR-CDA treatment followed by a gradual recovery. In addition, control tumors showed a slow decline in NG2⁺ pericyte coverage and a gradual decrease in CD8⁺ T cells, while RR-CDA-treated tumor showed increased pericyte coverage and a dramatic influx of CD8⁺ T cells at seven days after RR-CDA treatment. Of note, increased pericyte coverage, one of the hallmarks of tumor vessel normalization, coincided with the time of peak CD8⁺ T-cell infiltration into the TME.

To further dissect the effects of intratumoral STING activation on TME, LLC tumor-bearing mice were treated with repeated injections of the STING agonists, cGAMP or RR-CDA. After three consecutive intratumoral cGAMP injections, tumor growth was reduced by 46% compared with controls (Figure 3A). TME analyses revealed that cGAMP treatment led

to a 6.4-fold increase in intratumoral CD8⁺ T cells, 40% reduction in CD31⁺ blood vessel density, a 1.7-fold increase in NG2⁺ pericyte coverage, and 1.5-fold increase in COL4⁺ basement membrane coverage. Additionally, intratumoral hypoxia was alleviated by 46% in cGAMP-treated tumors compared to controls (Figure 3, B and C). Two injections of RR-CDA induced similar changes in the TME of LLC tumors: 41% delayed tumor growth, a 16.5-fold increase in intratumoral CD8⁺ T cells, a 51% decrease in CD31⁺ blood vascular density, a 4.4-fold increase in NG2⁺ pericyte coverage, and a 3.1-fold increase in COL4⁺ basement membrane coverage compared with controls. Moreover, glucose transporter 1 (GLUT1) level was analyzed as a hypoxia marker as previously described (21, 27), revealing a 46% decrease in intratumoral hypoxia after RR-CDA injection compared with controls (Figure 3, D–F).

In order to define the dose-ranging effect of STING agonist, we intratumorally injected 1~100 µg of RR-CDA into LLC tumors. RR-CDA effectively suppressed tumor growth even with a dose of 1 µg (Supplementary Figure 3, A and B), but its anti-angiogenic and vascular normalizing effect was seen at a dose of 5 µg or more (Supplementary Figure 3, C and D). When the dose of intratumoral RR-CDA was increased up to 100 µg, all tumors had completed regressed.

Overall, these findings indicate that STING activation can augment intratumoral CD8⁺ T-cell infiltration, normalized tumor vessels, and alleviated hypoxia within the tumor.

STING signaling pathway regulates tumor vascular and immune microenvironment.

To examine how STING signaling is involved in tumor vascular normalization, we investigated how STING agonist affected the TME in STING-deficient (*STING^{gt/gt}*, KO) and wild-type (WT) mice (Figure 4). In WT mice, intratumoral administration of cGAMP suppressed LLC tumor growth by 47%, reduced tumor vessel density by 48% and the number of vascular sprouts by 55%, and increased pericyte coverage by 1.7-fold. However, no changes

in tumor growth or tumor vessels were observed in KO mice, indicating that the cGAMP-induced anti-angiogenic effects were STING-dependent. Moreover, in the absence of cGAMP treatment, tumors of KO mice showed 1.4-fold higher blood vessel density, 1.5-fold increased number of vascular sprouts, and 47% decreased pericyte coverage compared with tumors of WT mice (Figure 4, A–C). Collectively, these findings suggest that STING signaling acts as a suppressor of sprouting tumor angiogenesis and an inducer of tumor vessel maturation.

To elucidate the transcriptional changes upon STING activation, we used the Nanostring PanCancer panel to compare 750 immune microenvironment-related genes in cGAMP-treated tumors in WT mice and tumors from KO mice. The results revealed dramatic differences between the STING-activated and STING-deficient TMEs (Figure 5A). At first, intratumoral STING activation strongly induced both type I IFNs and type II IFNs within TME (Figure 5B). Next, vascular stabilizing genes (e.g., *Cdh5*, *Angpt1*, *Pdgfrb*, *Mcam*, and *Col4a*) were also increased after STING activation, which were decreased or unchanged in KO mice (Figure 5C). On the other hand, vascular destabilizing genes did not differ significantly between groups (Figure 5D). We also compared various adhesion molecules that are critical in endothelial–lymphocyte interactions and lymphocyte transmigration, and found that STING activation significantly upregulated adhesion molecules, including *Icam*, *Vcam*, and *Sell* (Figure 5E). The full list of other gene changes is provided as Supplementary Table 4 and Supplementary Figure 3, E and F.

Since STING signaling is critical for myeloid cell activation (8), we also analyzed genes involved in macrophage polarization (Supplementary Figure 4, A and B). STING activation was associated with marked increases in genes specific for M1-like macrophages, while genes for M2-like macrophages were not significantly altered. This was confirmed by treating tumors with cGAMP or RR-CDA, and we found an increase in NOS2⁺ M1-like macrophages while CD206⁺ M2-like macrophages were not significantly altered compared

with control (Supplementary Figure 4, C–E). Consistently, flow cytometric analysis also revealed an accumulation of M1-like macrophages but no changes in M2-like macrophages, yielding an increasing trend in the M1/M2 ratio (Supplementary Figure 4F). We then examined the role of macrophages after intratumoral STING agonist treatment by selectively depleting macrophages with clodronate liposome (Supplementary Figure 4G) (28). Intriguingly, the anti-tumor efficacy of RR-CDA did not change significantly even after macrophages depletion (Supplementary Figure 4, H and I). Therefore, although intratumoral STING agonist treatment stimulates the accumulation of M1-like macrophages within the TME, macrophages seem to be dispensable for the overall anti-tumor effect of STING agonists.

Finally, we have found that intratumoral STING activation triggered an increase in inhibitory (e.g., *Pd-1*, *Pd-11*, *Ctla-4*, *Lag-3*, and *Tim-3*) and agonistic (e.g., *Icos*, *Ox40*, *Gitr*, *Hvem*, and *Cd27*) immune checkpoint genes (Figure 5F). We also confirmed increased in PD-1⁺CD8⁺ T cells, CTLA-4⁺CD8⁺ T cells, TIM-3⁺CD8⁺ T cells, and PD-L1⁺CD45⁺ cells in TME of STING-treated tumors (Figure 5G).

Collectively, our findings indicate that activation of STING signaling negatively regulates tumor angiogenesis in the TME and upregulates genes involved in vascular normalization, endothelial–lymphocyte interaction, and immune checkpoints.

STING in non-hematopoietic cells is as important as STING in hematopoietic cells during the therapy with exogenous STING agonist.

Although the role of STING signaling are mostly well-delineated in hematopoietic immune cells, its role in non-hematopoietic stromal cells are not so well-defined, even though these cells also express STING. To investigate the roles of hematopoietic-derived cells or non-hematopoietic stromal cells such as endothelial cells in the therapeutic efficacy of STING agonists, we generated chimeric mice by transferring WT or KO bone marrow into lethally

irradiated WT or KO mice to which we subcutaneously implanted LLC tumor cells (Figure 6A). When the tumors were intratumorally treated with RR-CDA, tumor growths were significantly suppressed in WT \rightarrow WT (bone marrow donor: WT, recipient: WT) mice, partially suppressed in KO \rightarrow WT or WT \rightarrow KO mice, but not suppressed in KO \rightarrow KO mice (Figure 6, B and C), indicating that both hematopoietic and non-hematopoietic STING is important for the anti-cancer effects of STING agonist treatment. Intriguingly, KO \rightarrow WT mice showed decreased tumor angiogenesis and increased pericyte coverage with less intratumoral CD8⁺ T cells. On the other hand, WT \rightarrow KO mice showed more intratumoral CD8⁺ T cells with less pronounced suppression of tumor angiogenesis and decrease in pericyte coverage (Figure 6, D and E). Therefore, it seems that STING in non-hematopoietic cells is more important in the regulation of tumor vessels, whereas STING in hematopoietic cells is more important in determining the magnitude of anti-cancer immune response by CD8⁺ T cells within the tumor.

Taken together, these results suggest that STING in non-hematopoietic cells is as important as STING in hematopoietic cells to induce a maximal therapeutic efficacy of exogenous STING agonist treatment.

TME regulation by STING activation is dependent on type I IFN signaling and CD8⁺ T cells.

To determine which immune system elements were responsible for STING-induced TME remodeling, we treated tumors with neutralizing antibodies against IFNAR or CD8. IFNAR depletion completely negated and, CD8 depletion partially (~40%) abrogated the anti-tumor efficacy of STING agonist treatment (Figure 7, A and B; Supplementary Figure 5, A and B). Notably, blockade of type I IFN signaling or depletion of CD8⁺ T cells also abrogated STING agonists' anti-angiogenic and vascular normalizing effects (Figure 7, C and D). This also nullified the STING-induced upregulation of genes involved in vascular normalization and

endothelial–lymphocyte interaction (Figure 7, E–G), and countervailed the beneficial effects of STING agonist against intratumoral hypoxia (Supplementary Figure 5, C and D). Furthermore, depletion of either IFNAR or CD8 with a neutralizing antibody almost negated the upregulation of M1-specific genes (Supplementary Figure 5, E and F).

These results indicate that type I IFN signaling and CD8⁺ T cells are indispensable for the STING-induced remodeling of tumor vasculatures. Since the impact of IFNAR depletion seem more powerful than that of CD8 depletion and the degree of vascular remodeling mediated by IFNAR and CD8 seems comparable, it seems that IFNAR signaling provides a more widespread effects on the immune cells, probably through innate immune cells rather than CD8⁺ T cells.

STING agonist treatment combined with VEGFR2 blockade induces complete tumor regression and enhances vascular normalization in established tumors.

Type I IFN signaling is negatively regulated by VEGF signaling (29). Thus, we questioned whether blocking VEGF signaling could further enhance STING-induced type I IFN activation, and reinforce STING-induced vascular normalization and anti-tumor immunity. To explore this combinatorial potential, we examined the effects of VEGFR2 blockade with or without cGAMP treatment in LLC tumors. Treatment with cGAMP and the VEGFR2 antibody, DC101 (25 mg/kg), led to 73% reduced tumor growth compared with control, which was 45% or 61% reduced tumor growth compared with cGAMP or DC101 monotherapy, respectively (Figure 8, A and B). Combined treatment with cGAMP and DC101 also led to a 47% reduction in CD31⁺ blood vascular density and a 1.3-fold increase in NG2⁺ pericyte coverage compared with cGAMP monotherapy (Figure 8, C and D). Of note, combination treatment with RR-CDA (25 µg, twice), instead of cGAMP, and DC101 induced complete tumor regression in all LLC tumor-bearing mice (Figure 8, E–G). Accordingly, the mice treated with both RR-CDA and

DC101 did not die, while the control, DC101 monotherapy, and RR-CDA monotherapy groups had median survival rates of 26, 25, and 38 days, respectively (Figure 8H). These results were recapitulated in the CT26 colon cancer model, in which we observed comparable synergistic anti-cancer effects; most of CT26 tumors had completely regressed after the combination therapy of RR-CDA and DC101 (Supplementary Figure 6, A and B), which also exhibited similar tumor vessel normalization and increased CD8⁺ T-cell infiltration (Supplementary Figure 6C).

To delineate the mediators of the response to combination therapy of STING agonists and DC101, we depleted either IFNAR, CD8⁺ T cells, or macrophages. Intriguingly, while neutralization of either IFNAR or CD8 almost completely negated the efficacy of RR-CDA and DC101 treatment and the tumor no longer showed complete regression, the anti-tumor effects of this combination therapy was maintained after the depletion of macrophages (Supplementary Figure 7, A and B).

Taken together, these data show that the combination of STING agonist and VEGFR2 blockade can induce complete tumor regression and durable anti-cancer immunity, with further enhancement of tumor vascular normalization. Moreover, the efficacy of dual combination therapy of STING agonist and VEGFR2 blockade largely depend on type I IFN signaling and CD8⁺ T cells, while macrophages are dispensable.

Triple combination immunotherapy of STING agonist, immune checkpoint inhibitor (α PD-1 or α CTLA-4), and anti-VEGFR2 antibody induces tumor regression.

Although STING activation triggered potent anti-tumor T-cell responses, it also led to a parallel induction of immune checkpoints in the TME, which would presumably generate a negative feedback loop (Figure 5, F and G). Since this could potentially restrain the STING - induced anti-cancer immunity, we evaluated the effects of combining immune checkpoint

inhibitors with STING agonist treatment and VEGFR2 blockade to maximize the anti-cancer efficacy (Figure 9A). Since the previous dose of RR-CDA (25 μ g, three times) already induced complete tumor regression in combination with DC101, its dose was decreased to 40 μ g (20 μ g, twice) for the following experiments. Although LLC tumors were completely resistant to immune checkpoint inhibitor (α PD-1 or α CTLA-4) monotherapy, combining RR-CDA to either α PD-1 (S + P) or α CTLA-4 (S + C) improved the anti-tumor effects compared with monotherapy, showing >35% complete response rates. Furthermore, when LLC tumors were treated with a triple combination immunotherapy with RR-CDA, α VEGFR2, and either α PD1 or α CTLA4 (S + V + P or S + V + C), more than half of tumor-bearing mice exhibited complete tumor regression (Figure 9, B and C) and consequently had improved overall survival (Figure 9D). Moreover, we found that the mice that experienced complete regression were immune to rechallenge with LLC tumor cells, but were vulnerable to MC38 tumor cells, suggesting the establishment of long-lasting tumor-specific immunological memory (Figure 9E). In summary, concurrent administration of immune checkpoint inhibitors can counteract STING-induced upregulation of immune checkpoints and potentiate the therapeutic efficacy of STING-targeted cancer immunotherapy, eventually leading to complete tumor regression and long-lasting immune memory against immunotherapy-resistant tumors.

The triple combination immunotherapy efficiently delays tumor growth and suppresses distant metastasis in a spontaneous breast cancer model.

Because subcutaneously implanted tumor models have poor and immature vasculatures and lack appropriate tumor stroma, they may not fully represent the biology of a real tumor immune microenvironment. Therefore, we employed a spontaneous breast cancer model, *MMTV-PyMT*, which has more mature tumor vasculatures and abundant stromal cells and is therefore a reliable representative of human breast cancer (30, 31), to further validate the

efficacy of STING activation in combination with VEGFR2 blockade and immune checkpoint inhibition (Figure 10A). After 3 weeks of treatment, RR-CDA alone remarkably delayed tumor growth not just in the STING-injected tumor but also non-injected tumors, suggesting abscopal anti-tumor effects upon STING activation; this was further strengthened by adding VEGFR2 blockade (S + V), and the triple combination therapy of RR-CDA, DC101, and anti-PD1 antibody (S + V + P) displayed the most potent tumor growth inhibition effect (Figure 10, B and C). Similarly with our previous observations, both dual and triple combination therapy led to a remarkable increase in intratumoral CD8⁺ T-cell infiltration, a decrease in tumor vessel density, and enhanced pericyte coverage (Figure 10, D and E). Moreover, triple combination immunotherapy markedly reduced hematogenous lung metastases (Figure 11, A and B) and prolonged the overall survival of *MMTV-PyMT* mice (Figure 11C). Taken together, these results demonstrate that STING agonist treatment, combined with VEGFR2 and PD-1 inhibition, can effectively inhibit tumor progression and metastasis through vascular normalization and bolstered anti-cancer immune response (Figure 11D).

Discussion

Our present findings demonstrated the importance of STING signaling in tumor vascular reprogramming, and support the clinical applicability of STING agonists for anti-angiogenic immunotherapy in cancer treatment. Vascular STING expression in tumor tissue correlated with favorable prognosis in human malignancies, and intratumoral activation of STING signaling by exogenous STING agonists induced quantitative and qualitative changes of tumor vasculature. Upon STING activation, tumor vessels underwent a transient phase of initial vascular disruption and then became normalized with enhanced pericyte coverage and upregulation of endothelial–leukocyte adhesion molecules. This process facilitated the intratumoral trafficking of effector T cells across the endothelial barrier and conditioning of the TME to enhance anti-tumor immunity. Most importantly, simultaneous blockade of VEGFR2 and/or immune checkpoint molecules (PD-1 or CTLA-4) amplified the anti-tumor efficacy of STING agonists, promoting complete tumor regression and prolonged survival in mice with tumors that were resistant to immunotherapy or anti-angiogenic therapy alone.

STING-induced vascular remodeling was found to involve multiple TME components that are closely intertwined with each other. Most of all, type I IFNs were indispensable mediators of STING-induced vascular reprogramming. IFN- β is a potent anti-angiogenic cytokine that inhibits endothelial proliferation, survival, and capillary network formation, which induces vascular maturation in tumors through angiopoietin-1 upregulation (32–34). Consistently, our findings revealed that intratumoral STING agonist treatment led to the activation of type I IFN signaling, accompanied by upregulation of vascular normalizing genes such as *Angpt1*, *Pdgfrb*, *Mcam*, *Cdh5*, and *Col4a*. These transcriptional changes eventually induced tumor vessel normalization with enhanced pericyte coverage and more intact basement membrane, which promoted intratumoral infiltration of effector CD8⁺ T cells and alleviated hypoxia in the TME. Notably, blocking type I IFN signaling by IFNAR inhibition almost

completely abrogated STING-induced transcriptional alterations and vascular phenotypical changes, indicating a critical role of type I IFNs in STING-induced vascular reprogramming.

Another important component of STING-induced vascular reprogramming is non-hematopoietic stromal cells, such as endothelial cells. As revealed through our bone marrow chimera experiments, STING in non-hematopoietic cells is as important as STING in hematopoietic cells to elicit maximal therapeutic efficacy of exogenous STING agonists. Especially, STING in non-hematopoietic cells seems to be more important in anti-angiogenic and vascular normalizing effects of STING agonists compared with STING in hematopoietic cells. Among various stromal cell components in TME, endothelial cells seem to be the key players after STING activation for several reasons. First, they showed the most distinct STING expression compared with other stromal cells. Moreover, they can produce excess IFN- β upon stimulation with STING agonists and, in turn, IFN- β can directly act on endothelial cells, presumably in an autocrine or paracrine manner (6, 23). Furthermore, endothelial cells may not only be the dominant source of type I IFNs and but also their most important target in TME, as they are more abundant than dendritic cells and most tumors are highly angiogenic (23). However, the definite role of endothelial cells and other stromal components of TME should be deciphered through further studies using cell-type specific conditional KO mice.

Innate immune cells are universally found within TME and are also involved in the STING-mediated remodeling of TME. For this process, the most important cell type seems to be dendritic cells, since they produce IFN- β robustly upon stimulation with STING agonists and the activation of type I IFN signaling in the dendritic cells is critical for CD8⁺ T-cell priming against tumor antigens (6, 35). Another abundant innate immune cells within TME are macrophages. Environmental signals cause macrophages to undergo reversible phenotypic switching into either M1- or M2-like macrophages, which are proposed to suppress and promote tumor angiogenesis, respectively (13, 36, 37). Our results indicated that intratumoral

STING activation preferentially upregulated M1-specific genes and accumulated M1-like macrophages within TME. These phenotypic changes in macrophages seem to be consequences rather than causes of STING agonist-mediated remodeling of TME, given that the depletion of macrophages did not attenuate the efficacy of STING agonists. However, because the macrophages do not seem to be completely depleted by clodronate liposome, it would be difficult to completely rule out the possible contribution of macrophages in STING-induced anti-tumor activity.

Tumor-infiltrating T lymphocytes also play an important role in the TME, and were found to be involved in STING-mediated vascular remodeling. Anti-angiogenic therapy strengthens T-cell-mediated anti-tumor immunity by enhancing lymphocyte infiltration into the tumor, and growing evidence suggests the reciprocal effects of T lymphocytes on tumor vasculatures (15, 22, 38). CD8⁺ cytotoxic T cells and T_H1 cells secrete IFN- γ , which inhibits tumor angiogenesis by restraining endothelial cell proliferation and upregulating cytokine-encoding genes (e.g., CXCL9, CXCL10, and CXCL11) that stimulate pericyte recruitment (13, 18). Moreover, IFN- γ primarily causes regression of immature tumor endothelial cells that are devoid of pericytes, while those with pericytes can endure IFN- γ -mediated vascular damage (39). Therefore, tumor-infiltrating T cells that secrete IFN- γ may also contribute to vascular and immune remodeling.

Monotherapy with a STING agonist exhibited outstanding anti-tumor efficacy through vascular normalization and T-cell influx to the TME in vivo. However, this could be limited by opposing mechanisms (40, 41). Type I IFN signaling is negatively regulated by VEGF-VEGFR2 signaling through ubiquitin-mediated IFNAR degradation (29, 34), such that STING agonist treatment may not sufficiently activate type I IFN signaling in VEGF-rich cancers. Additionally, while repeated STING agonist injections induced strong innate and adaptive immunity, this would inevitably upregulate immune checkpoint molecules, generating a negative feedback loop that might confer adaptive resistance to STING agonist-induced

immune responses, ultimately enabling tumor relapse (42–44). This suggests that a combination strategy targeting VEGF-VEGFR2 signaling and/or immune checkpoint signaling might be needed to maximize and sustain the anti-cancer efficacy of STING-based immunotherapy, especially in the clinical setting where patients will be repeatedly exposed to STING agonists over a long time period. Indeed, our findings demonstrated that triple combination immunotherapy, with STING agonist, anti-VEGFR2 antibody, and either anti-PD-1 or anti-CTLA-4 antibody, yielded superior and durable anti-tumor efficacy compared with monotherapy or dual combination therapy. Future clinical trials should investigate and validate this novel triple combination strategy, especially for patients with poorly immunogenic and highly angiogenic tumors that do not respond to conventional immune checkpoint blockade.

Intratumoral delivery of immunostimulatory drugs has an advantage of achieving much higher concentration of drugs and immunostimulatory products in TME than do systemic administration. Moreover, it can sometimes induce abscopal effects, the regression of untreated tumors at a distant site, which enables the effective control of distant metastases (45). Though abscopal effects could be induced considerably in preclinical mouse cancer models, it is limited in cancer patients with multiple systemic metastases because human immune system is more complex and extensive than that of mouse. For this reason, many studies tried to enhance the abscopal effect of intratumoral immunotherapy by combining with a systemic treatment (45). In our study with *MMTV-PyMT* spontaneous breast model, which has multiple synchronous breast cancer nodules and lung metastases, intratumoral injection of STING agonist successfully delayed the growth of both injected and non-injected tumors. Intriguingly, the degree of abscopal effect was further strengthened with simultaneous systemic treatment of VEGFR2 and PD1 blockade, which led to higher accumulation of CD8⁺ T cells into the tumors. Therefore, simultaneous VEGFR2 blockade could overcome the limitations of intratumoral immunotherapy and enhance the efficacy of STING therapy in future clinical trials.

In addition to its promising efficacy, STING-based triple combination immunotherapy also has the advantage of minimizing systemic treatment-related toxicities. Combination immunotherapies with anti-PD-1 and anti-CTLA-4 antibodies already show superiority over monotherapy in various malignancies, but sometimes lead to fatal toxicities, particularly caused by synergistic hyperactivation of systemic immunity (46, 47). In contrast, STING-based immunotherapy can minimize such systemic toxicities because STING agonists are delivered intratumorally and not systemically. In our study, we observed no treatment-related gross abnormalities or lethality in the tumor-bearing animals treated with STING-based triple combination therapy. There remains the risk that intratumoral injection of STING agonists may cause local injection site reactions. Previous studies report ulcerative or hemorrhagic changes of tumors following treatments with various STING agonists, which are reportedly caused by TNF- α secreted from STING-activated myeloid cells (6, 8, 11). We also observed hemorrhagic crusts covering the tumor masses of regressing tumors after STING-based triple immunotherapy. However, these skin lesions were self-limited and completely resolved within 2~3 weeks of treatment. This suggests that STING-based triple immunotherapy will be generally well-tolerated, except for the self-limited injection site reaction.

In conclusion, our results demonstrate that intratumoral STING activation normalizes tumor blood vessels and enhances anti-tumor immunity. STING agonist treatment activates type I IFN signaling, and it yields the most potent anti-tumor efficacy when combined with VEGFR2 and/or immune checkpoint blockades. These findings warrant further investigation of this novel combination strategy of STING-based immunotherapy in clinical trials.

Methods

Mice and cell lines. Male C57BL/6 or BALB/c mice of 6–8 weeks of age were obtained from Orient Bio Inc. (Seongnam, Korea). Male *C57BL/6J-Tmem173^{gt/gt}* mice (STING^{gt/gt}) (#017537) and female *MMTV-PyMT* transgenic mice (FVB/N) (#002374) were purchased from Jackson Laboratory (Bar Harbor, ME, USA). All the mice were housed in a specific pathogen-free animal facility at CHA University (Seongnam, Korea). Lewis lung carcinoma (LLC) and CT26 colon cancer cells were purchased from American Type Culture Collection (Manassas, VA, USA). MC38 colon cancer cells were obtained from National Cancer Center, Korea. These cells were cultured at 37 °C under 5% CO₂ in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin.

Tumor models and treatment regimens. We implanted 5×10^5 LLC and 2×10^5 CT26 cells into the right flank of C57BL/6 and BALB/c mice, respectively. When the tumors reached > 4–5 mm in diameter, we performed intratumoral injections of the STING agonist 3'3'-cGAMP (10 µg, cGAMP, Invivogen) or 2'3'-c-di-AM(PS)₂ (25 µg, RR-CDA, also called MIW815 or ADU-S100, Invivogen) at the given time-points. Mice in the control group were intratumorally injected with the same volume of PBS. For combination therapy, we also performed intraperitoneal injections of VEGFR2-blocking antibody (25 mg/kg, clone DC101, BioXCell) at given time-points. For the cell depletion study, each mouse received intraperitoneal injections of 200 µg anti-IFNAR (clone MAR1-5A3, BioXCell), anti-CD8 (clone 53-6.72, BioXCell), anti-IFN-γ (clone XMG1.2, BioXCell), or 500 µg anti-TNF-α (clone XT3.11, BioXCell) antibody every three days. For the macrophage cell depletion study, each mouse received intraperitoneal injection of 200 µl Clodronate liposome or Control liposome (Liposoma), three or four times, as described previously (28). For immune checkpoint blockade, the mice received intraperitoneal injection of anti-PD-1 (10 mg/kg, clone J43, BioXCell) or

anti-CTLA-4 (4 mg/kg, clone 9D9, BioXCell) antibody at the given time-points. The surviving mice with complete tumor regression were rechallenged with 5×10^5 LLC cells or MC38 cells in the left flank, and the tumor growth was monitored. The tumor volumes were measured with calipers and calculated using the following modified ellipsoid formula: $1/2 \times (\text{length} \times \text{width}^2)$. For survival analysis, the mice were euthanized once the tumors exceeded 2500 mm³ in volume or when the mice became moribund. *MMTV-PyMT* mice that were 9 weeks old were administered with intratumoral injections of STING agonist (25 µg/nodule, RR-CDA) on four nodule sites per mouse and intraperitoneal injections of anti-VEGFR2 and/or anti-PD-1 antibodies twice per week for 3 weeks. For survival analysis, the mice were euthanized once the tumors volume exceeded 1500 mm³ or when the mice became moribund.

Analyses of human tumor samples. The survival outcomes and clinicopathologic data were obtained from the electronic medical records of the institute. Overall survival was defined as the time interval between the diagnosis of cancer and death or last follow-up. Immunohistochemical staining was performed using antibodies against STING (rabbit, clone D1V5L, Cell Signaling) or CD8 (rabbit, clone SP57, Roche) on 5-µm-thick sections cut from formalin-fixed paraffin-embedded tissue microarray blocks of 3-mm core size. The visualization systems used were the BenchMark XT (Ventana) with heat-induced epitope retrieval (CC1 solution, Ventana) and the iView DAB detection kit (Ventana). Before mounting, the slides were counter-stained with hematoxylin. High-resolution digital images of the stained slides were acquired using a BX43 microscope (Olympus). Lymphovascular invasion was defined as the presence of tumor cells within a vascular lumen which are intimately admixed with blood cells and focally adherent to or within the vessel wall. Density measurement of STING or CD8 for every stained core of tissue microarray was performed with the ImageJ software running the Fiji image processing package (<https://imagej.net/Fiji>). The color

channels with hematoxylin and diaminobenzidine were separated and quantified to determine the immunoreactive areas. Particularly, the degree of endothelial STING expression was calculated as the mean perimeter of STING positivity around the entire circumference of ≥ 10 representative tumor blood vessels per core. The cut-off values for high and low STING expression were the median of all the samples of the corresponding cancer type.

Statistical analysis. The statistical analyses were performed using GraphPad Prism 7.0 software (GraphPad Software, La Jolla, CA) and PASW statistics 18 (SPSS). The values are presented as mean \pm standard error (SD) unless otherwise indicated. The statistical differences were assessed using unpaired two-tailed Student's *t* test, chi-square tests, or ANOVA with Tukey post hoc test. Pearson's correlation analysis was performed to investigate the relationship between CD8⁺ T-cell expression and endothelial STING expression. Waterfall plots present the maximal percent changes of each tumor at the end of the experiment compared with their baseline volume. The survival curves were generated using the Kaplan-Meier method, and the statistical differences were analyzed with the log-rank test. Multivariate analyses for overall survival were conducted with a Cox proportional hazard model. The statistical significance was set at $P < 0.05$.

Study approval. The animal experiments were performed according to the animal experimental guideline upon the approval of the Institutional Animal Care and Use Committee of CHA University (IACUC 150080). All the human samples were collected with informed consent from patients at CHA Bundang Medical Center (Seongnam, Korea). All the procedures were approved by the institutional review board of CHA Bundang Medical Center (IRB No. 2017-11-054).

Author contributions

HY, WSL, HJC, and CK were responsible for the study concept and design. HY, WSL, SJK, JHK, SKC, SK, GK, HJC, and CK conducted the experiments. HY, WSL, CGK, HJC, and CK performed data analysis. HY, HJC, and CK generated the figures and wrote and reviewed the manuscript. CK and HJC supervised the study, obtained funding, and drafted the manuscript.

Acknowledgements

This study was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (NRF-2016R1C1B2014671 to C.K.) and by the Bio & Medical Technology Development Program of the National Research Foundation (NRF-2016M3A9E8941664 to H.C).

References

1. Woo S-R, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. *Immunity*. 2014;41(5):830-42.
2. Barber GN. STING: infection, inflammation and cancer. *Nat Rev Immunol*. 2015;15(12):760.
3. Gajewski TF. The next hurdle in cancer immunotherapy: Overcoming the non-T-cell-inflamed tumor microenvironment. *Semin Oncol*. 2015;42(4):663-71.
4. Corrales L, and Gajewski TF. Molecular pathways: targeting the stimulator of interferon genes (STING) in the immunotherapy of cancer. *Clin Cancer Res*. 2015;21(21):4774-9.
5. Vargas TR, Benoit-Lizon I, and Apetoh L. Rationale for stimulator of interferon genes-targeted cancer immunotherapy. *Eur J Cancer*. 2017;75:86-97.
6. Corrales L, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. *Cell reports*. 2015;11(7):1018-30.
7. Fu J, et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. *Sci Transl Med*. 2015;7(283):283ra52.
8. Ager CR, Reilley MJ, Nicholas C, Bartkowiak T, Jaiswal AR, and Curran MA. Intratumoral STING activation with T-cell checkpoint modulation generates systemic antitumor immunity. *Cancer Immunol Res*. 2017;5(8):676-684.
9. Ohkuri T, et al. STING contributes to anti-glioma immunity via triggering type-I IFN signals in the tumor microenvironment. *Cancer Immunol Res*. 2014;2(12):1199-208.
10. Foote JB, et al. A STING agonist given with OX40 receptor and PD-L1 modulators primes immunity and reduces tumor growth in tolerized mice. *Cancer Immunol Res*. 2017;5(6):468-479.
11. Baird JR, et al. Radiation therapy combined with novel STING-targeting

- oligonucleotides results in regression of established tumors. *Cancer Res.* 2016;76(1):50-61.
12. Ishikawa H, and Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. *Nature.* 2008;455(7213):674-8.
 13. De Palma M, Biziato D, and Petrova TV. Microenvironmental regulation of tumour angiogenesis. *Nat Rev Cancer.* 2017;17(8):457-74.
 14. Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. *Cancer Cell.* 2014;26(5):605-22.
 15. Khan KA, and Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. *Nat Rev Clin Oncol.* 2018;15(5):310-24.
 16. De Palma M, and Jain RK. CD4⁺ T cell activation and vascular normalization: Two sides of the same coin? *Immunity.* 2017;46(5):773-5.
 17. Carman CV, and Martinelli R. T Lymphocyte–endothelial interactions: emerging Understanding of Trafficking and Antigen-Specific immunity. *Front Immunol.* 2015;6:603.
 18. Tian L, et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. *Nature.* 2017;544(7649):250-4.
 19. Allen E, et al. Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation. *Sci Transl Med.* 2017;9(385):eaak9679.
 20. Kim C, et al. Vascular RhoJ is an effective and selective target for tumor angiogenesis and vascular disruption. *Cancer Cell.* 2014;25(1):102-17.
 21. Park J-S, et al. Normalization of tumor vessels by Tie2 activation and Ang2 inhibition enhances drug delivery and produces a favorable tumor microenvironment. *Cancer Cell.* 2016;30(6):953-67.
 22. Fukumura D, Kloepper J, Amoozgar Z, Duda DG, and Jain RK. Enhancing cancer

- immunotherapy using antiangiogenics: opportunities and challenges. *Nat Rev Clin Oncol*. 2018;15(5):325-40.
23. Demaria O, et al. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. *Proc Natl Acad Sci U S A*. 2015;112(50):15408-13.
24. Baird JR, et al. STING expression and response to treatment with STING ligands in premalignant and malignant disease. *PloS one*. 2017;12(11):e0187532.
25. Liu Y, et al. Activated STING in a vascular and pulmonary syndrome. *N Engl J Med*. 2014;371(6):507-18.
26. Chen Q, Sun L, and Chen ZJ. Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing. *Nature Immunol*. 2016;17(10):1142-9.
27. Jang JY, et al. VEGFR2 but not VEGFR3 governs integrity and remodeling of thyroid angiofollicular unit in normal state and during goitrogenesis. *EMBO Mol Med*. 2017;9(6):750-69.
28. Yang H, et al. Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer. *Mol Cancer*. 2011;10:36.
29. Zheng H, et al. Vascular endothelial growth factor-induced elimination of type 1 interferon receptor is required for efficient angiogenesis. *Blood*. 2011;118(14):4003-6.
30. Lin EY, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. *Am J Pathol*. 2003;163(5):2113-26.
31. Chon HJ, et al. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade. *Clin Cancer Res*. 2019;25(5):1612-23.
32. Dickson PV, et al. Continuous delivery of IFN- β promotes sustained maturation of

- intratumoral vasculature. *Mol Cancer Res.* 2007;5(6):531-42.
33. Jia H, et al. Endothelial cell functions impaired by interferon in vitro: Insights into the molecular mechanism of thrombotic microangiopathy associated with interferon therapy. *Thromb Res.* 2018;163:105-16.
34. Sidky YA, and Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. *Cancer Res.* 1987;47(19):5155-61.
35. Gajewski TF, Schreiber H, and Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. *Nat Immunol.* 2013;14(10):1014-22.
36. Caux C, Ramos RN, Prendergast GC, Bendriss-Vermare N, and Ménétrier-Caux C. A milestone review on how macrophages affect tumor growth. *Cancer Res.* 2016;76(22):6439-42.
37. Albini A, Bruno A, Noonan DM, and Mortara L. Contribution to Tumor Angiogenesis From innate immune Cells within the Tumor Microenvironment: implications for immunotherapy. *Front Immunol.* 2018;9:527.
38. Schmittnaegel M, and De Palma M. Reprogramming tumor blood vessels for enhancing immunotherapy. *Trends Cancer* 2017;3(12):809-12.
39. Kammertoens T, et al. Tumour ischaemia by interferon- γ resembles physiological blood vessel regression. *Nature.* 2017;545(7652):98-102.
40. Ivashkiv LB, and Donlin LT. Regulation of type I interferon responses. *Nat Rev Immunol.* 2014;14(1):36-49
41. Terawaki S, et al. IFN- α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. *J Immunol.* 2011;186(5):2772-9.
42. Mandai M, Hamanishi J, Abiko K, Matsumura N, Baba T, and Konishi I. Dual faces of IFN- γ in cancer progression: a role of PD-L1 induction in the determination of pro-and anti-tumor immunity. *Clin Cancer Res.* 2016;22(10):2329-34.

43. Sharma P, Hu-Lieskovan S, Wargo JA, and Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. *Cell*. 2017;168(4):707-23.
44. Ribas A. Adaptive immune resistance: how cancer protects from immune attack. *Cancer Discov*. 2015;5(9):915-9.
45. Marabelle A, et al. Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). *Ann Oncol*. 2018;29(11):2163-74
46. Tang C, Jiang W, and Yap TA. Efficacy and Toxic Effects of Cancer Immunotherapy Combinations—A Double-Edged Sword. *JAMA Oncol*. 2018;4(8):1116-1117.
47. Spain L, Diem S, and Larkin J. Management of toxicities of immune checkpoint inhibitors. *Cancer Treat Rev*. 2016;44:51-60.

Figure legends




Figure 1. Endothelial STING expression correlates with intratumoral CD8⁺ T-cell infiltration and favorable prognosis in human cancers

Clinical implications of endothelial STING expression (Endo STING) in breast cancer (n = 173) and colorectal cancer (n = 160).

(A–B) Representative images of STING and CD8 expressions in human breast cancer (A) and colorectal cancer (B).

(C–D) Correlation between endothelial STING expression and intratumoral CD8⁺ cells in

breast cancer (**C**) and colorectal cancer (**D**). *R* and *P* values by Pearson's correlation test.

(**E–F**) Kaplan-Meier survival curves of breast cancer patients (**E**) and colorectal cancer patients (**F**) according to endothelial STING expression. *P* values by the log-rank test.




Figure 2. Intratumoral injection of STING agonist induces dramatic changes in tumor microenvironment.

LLC tumor cells were implanted subcutaneously into mice and treated with intratumoral injections of PBS or STING agonists (S).

(A) Serial images of LLC tumors after a single injection of PBS or STING agonist (RR-CDA, 25 μ g). Arrowheads indicate disrupted tumor vessels.

(B) Temporal changes in CD31⁺ blood vessels, NG2⁺ pericyte coverage, and CD8⁺ T cells after a single injection of PBS or STING agonist treatment.

Pooled data from two independent experiments with $n = 5$ to 6 per group. Scale bars, 50 μ m.




Figure 3. STING agonists promote CD8⁺ T-cell responses and tumor vascular normalization.

LLC tumor cells were implanted subcutaneously into mice and treated with intratumoral injections of PBS or STING agonists (S). Red arrows indicate treatment and black arrow indicates mice sacrifice.

(A) Comparison of LLC tumor growth in mice treated with PBS or STING agonist (cGAMP, 10 μ g).

(B–C) Representative images (B) and comparisons (C) of CD8⁺ T cells, CD31⁺ blood vessels, NG2⁺ pericyte coverage, COL4⁺ basement membrane (BM) coverage, and hypoxic area.

(D) Comparison of LLC tumor growth in mice treated with PBS or STING agonist (RR-CDA, 25 μ g).

(E–F) Representative images (E) and comparisons (F) of CD8⁺ T cells, CD31⁺ blood vessels, NG2⁺ pericyte coverage, COL4⁺ BM coverage, and GLUT1⁺ hypoxic area.

Pooled data from two independent experiments with $n = 8$ to 9 per group. Values are mean \pm SD. $*P < 0.05$ versus PBS. Two-tailed Student t test. Scale bars, $50\ \mu\text{m}$.




Figure 4. STING signaling pathway regulates tumor angiogenesis.

LLC tumor cells were implanted subcutaneously into wild-type (WT) or STING-deficient mice (*STING*^{gt/gt}, KO) and treated with intratumoral injections of PBS or STING agonist (S).

(A) Comparison of tumor growth in mice treated with PBS or STING agonist. Red arrows indicate treatment and black arrow indicates mice sacrifice.

(B–C) Representative images (B) and comparisons (C) of CD31⁺ blood vessels, tumor vessel sprouts, and NG2⁺ pericyte coverage.

Pooled data from two experiments with $n = 8$ per group. Values are mean \pm SD. * $P < 0.05$ versus PBS. ANOVA with Tukey post-hoc test (A and C). Scale bars, 50 μ m.




Figure 5. STING signaling pathway regulates tumor vascular and immune microenvironment.

Wild-type (WT) or STING-deficient mice (*STING^{gt/gt}*, KO) were injected with LLC tumor cells and treated with intratumoral injections of PBS or STING agonist.

(A) Volcano plot showing gene expression changes in STING agonist-treated tumors of WT mice (red) and PBS-treated tumors of STING-deficient mice (blue).

(B–E) Comparison of gene expressions related to type I/II IFNs (B), vascular stabilization (C), vascular destabilization (D), and endothelial cell and lymphocyte interaction (E).

(F) Comparison of gene expressions related to inhibitory and agonistic immune checkpoints in tumors treated with STING agonist.

(G) Flow cytometric analyses of immune checkpoints in tumors.

Pooled data from two experiments with $n = 4$ to 9 per group. Values are mean \pm SD. $*P < 0.05$ versus PBS. Two-tailed Student t test (**B–G**).




Figure 6. STING in non-hematopoietic cells is as important as STING in hematopoietic cells during the therapy with exogenous STING agonist.

LLC tumor cells were implanted subcutaneously into bone marrow chimeric mice and treated with intratumoral injections of STING agonist (RR-CDA, 25 μ g). Red arrows indicate treatment and black arrow indicates mice sacrifice.

(A) Diagram depicting the generation of chimeric mice.

(B–C) Comparison of LLC tumor growth in bone marrow chimeric mice. Mean **(B)** and individual **(C)** tumor growth curve over time.

(D–E) Representative images **(D)** and comparisons **(E)** of CD8⁺ T cells, CD31⁺ blood vessels, and NG2⁺ pericyte coverage.

Pooled data from two experiments with n = 6 to 10 per group. Values are mean ± SD. * $P < 0.05$ versus WT → WT; # $P < 0.05$ versus KO → WT; \$ $P < 0.05$ versus WT → KO. ANOVA with Tukey post-hoc test **(B and E)**. Scale bars, 50 μm.




Figure 7. TME regulation by STING activation is dependent on type I IFN signaling and CD8⁺ T cells.

Mice were subcutaneously implanted with LLC tumor cells and treated with STING agonist

(S) and depleting antibodies for IFNAR (α IFNAR) or CD8⁺ T cells (α CD8).

(A–B) Comparison of tumor growth in mice. Mean (A) and individual (B) tumor growth curves over time. Red arrows indicate injections of cGAMP (10 μ g), blue arrows indicate injections of depleting antibodies, and black arrow indicates mice sacrifice.

(C–D) Representative images (C) and comparisons (D) of CD8⁺ T cells, CD31⁺ blood vessels, NG2⁺ pericytes coverage, and COL4⁺ BM coverage.

(E–G) Comparison of gene expression involved in vascular stabilization (E), vascular destabilization (F), and endothelial-lymphocyte interaction (G).

Pooled data from two experiments with $n = 6$ per group. Values are mean \pm SD. $*P < 0.05$ versus PBS; $\#P < 0.05$ versus S. ANOVA with Tukey post-hoc test (A and D–G). Scale bars, 50 μ m.




Figure 8. STING agonist treatment combined with VEGFR2 blockade induces complete tumor regression and enhances vascular normalization in established tumors.

Mice were subcutaneously implanted with LLC tumor cells and treated with STING agonist (S) and/or DC101 (V). Red arrows indicate injections of STING agonists, blue arrows indicate injections of DC101, and black arrow indicates mice sacrifice.

(A–B) Comparison of LLC tumor growth in mice treated with cGAMP (10 μg) and/or DC101.

Mean (**A**) and individual (**B**) tumor growth curves over time. The number of tumor-free mice is indicated for each group.

(**C–D**) Representative images (**C**) and comparisons (**D**) of CD31⁺ blood vessels and NG2⁺ pericyte coverage.

(**E–F**) Comparison of LLC tumor growth in mice treated with RR-CDA (25 µg) and/or DC101.

Mean (**E**) and individual (**F**) tumor growth curves over time. The number of tumor-free mice is indicated for each group.

(**G**) Waterfall plots showing the maximal percent changes of each tumor at the end of the experiment compared with their baseline volume.

(**H**) Kaplan-Meier survival curves for overall survival. * $P < 0.05$. Log-rank test.

Unless otherwise denoted: Pooled data from two experiments with $n = 6$ to 8 per group. Values are mean \pm SD. * $P < 0.05$ versus PBS; # $P < 0.05$ versus S; \$ $P < 0.05$ versus V. ANOVA with Tukey post-hoc test (**A**, **D**, and **E**). Scale bars, 50 µm.




Figure 9. Triple combination immunotherapy of STING agonist, immune checkpoint inhibitor (α PD-1 or α CTLA-4), and anti-VEGFR2 antibody induces tumor regression

Mice were subcutaneously implanted with LLC tumor cells and treated with STING agonist (S), DC101 (V), and α PD-1 (P) or α CTLA-4 (C).

(A) Diagram depicting treatment schedule.

(B) Comparison of LLC tumor growth in mice. The number of tumor-free mice is indicated for each group. PBS (black) or IgG (grey) were used as control.

(C) Waterfall plots showing the maximal percent changes of each tumor at the end of the experiment compared with their baseline volume.

(D) Kaplan-Meier survival curves for overall survival.

(E) Comparison of tumor growth after injection of LLC or MC38 tumor cells into naïve mice or mice with complete tumor regression.

Pooled data from two experiments with $n = 8$ to 16 per group. Values are mean \pm SD. $*P < 0.05$. Log-rank test (**D**). ANOVA with Tukey post-hoc test (**E**).




Figure 10. The triple combination immunotherapy efficiently delays tumor growth in both injected and non-injected tumors of a spontaneous breast cancer model.

Tumor growth was measured twice a week in a spontaneous breast tumor model, *MMTV-PyMT* mice, starting from 9 weeks after birth. Mice were treated with STING agonist (S), DC101 (V), and/or α PD-1 (P).

(A) Diagram depicting the treatment schedule. Red arrows indicate treatment and the black arrow indicates mice sacrifice.

(B) Representative images showing gross appearances of tumors. Dotted lines demarcate palpable tumor nodules. * indicates PBS or STING-injected lesion. Red arrows indicate lesions with complete tumor regression.

(C) Comparison of the growth of STING-injected or non-injected tumors in *MMTV-PyMT* mice.

(**D–E**) Representative images (**D**) and comparisons (**E**) of CD8⁺ T cells, CD31⁺ blood vessels, and NG2⁺ pericyte coverage.

Each group: n = 5 to 7 per group. Values are mean \pm SD. * $P < 0.05$. ANOVA with Tukey post-hoc test (**E**). Scale bars, 50 μm .




Figure 11. The triple combination immunotherapy suppresses lung metastases and provides survival benefit in a spontaneous breast cancer model.

Tumor growth was measured twice a week in a spontaneous breast tumor model, *MMTV-PyMT* mice, starting from 9 weeks after birth. Mice were treated with STING agonist (S), DC101 (V), and/or αPD-1 (P).

(A) Lung sections stained with H&E. Arrows indicate pulmonary metastatic lesions. Scale bars, 2 mm. Each group: n = 5 to 6 per group.

(B) Comparison of the number of metastatic colonies per lung section. Values are mean ± SD. * $P < 0.05$. ANOVA with Tukey post-hoc test.

(C) Kaplan-Meier survival curves for overall survival. Each group: n = 5 to 7 per group. Values

are mean \pm SD. $^*P < 0.05$ versus PBS; $^{\#}P < 0.05$ versus S; $^{\$}P < 0.05$ versus V; $^{\&}P < 0.05$ versus S + V. Log-rank test.

(D) Diagram depicting the mechanism by which STING activation reprograms TME and the rationale for STING-based combination immunotherapy.